Analyst Tracker/Patrick Trucchio

Patrick Trucchio

Q: How accurate are Patrick Trucchio's stock ratings?

About 48% of Patrick's ratings were profitable over a one-year hold, with an average return of +0.5% per rating, measured by 13Foresight from historical prices.

Q: How is Patrick ranked?

Patrick Trucchio is ranked #1581 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#1581

on 13Foresight · ranked by our own returns

48%

Success Rate

+0.5%

Average Return

94 of 196 calls profitable · +14.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 48% of Patrick Trucchio's ratings turned a profit when each position was held for 1 year — averaging +0.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

409 Buy 3 Hold 0 Sell

Patrick's Stock Coverage 41 ratings · 2026-10-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
HRMY Harmony Biosciences Holdings	Oct 13, 2026	BUY	Strong Buy +33.1% avg upside 14 analysts	$55.00 48.89% Upside	+5.1%	·
ALGS Aligos Therapeutics	Oct 08, 2026	BUY	Strong Buy +755.3% avg upside 11 analysts	$50.00 822.54% Upside	-1.5%	·
HELP Helus Pharma	Oct 08, 2026	BUY	Strong Buy +307.5% avg upside 14 analysts	$70.00 581.69% Upside	+10.1%	·
ASMB Assembly Biosciences	Oct 08, 2026	BUY	Strong Buy +80.2% avg upside 11 analysts	$50.00 145.86% Upside	-0.2%	·
ALT Altimmune	Oct 08, 2026	BUY	Strong Buy +997.2% avg upside 20 analysts	$20.00 743.81% Upside	+0.4%	·
VIR Vir Biotechnology	Oct 07, 2026	BUY	Strong Buy +142.6% avg upside 16 analysts	$22.00 103.21% Upside	+1.6%	·
PHVS Pharvaris	Oct 06, 2026	BUY	Strong Buy +85.0% avg upside 15 analysts	$60.00 100.98% Upside	-0.1%	·
AGMB AgomAb Therapeutics NV ADR	Oct 02, 2026	BUY	Strong Buy +301.3% avg upside 7 analysts	$35.00 305.03% Upside	+6.1%	·
IVVD Invivyd	Sep 30, 2026	BUY	Buy +1213.6% avg upside 8 analysts	$10.00 1552.86% Upside	-17.1%	·
QURE uniQure	Sep 30, 2026	BUY	Strong Buy +166.6% avg upside 30 analysts	$80.00 280.24% Upside	-13.2%	·
CMPS COMPASS Pathways	Sep 21, 2026	BUY	Strong Buy +98.6% avg upside 20 analysts	$65.00 491.38% Upside	-25.1%	·
ALNY Alnylam Pharma	Sep 21, 2026	BUY	Strong Buy +39.2% avg upside 51 analysts	$455.00 101.88% Upside	-8.1%	·
ARWR Arrowhead Pharmaceuticals	Sep 21, 2026	BUY	Strong Buy +23.4% avg upside 28 analysts	$120.00 105.55% Upside	-11.7%	·
ONCY Oncolytics Biotech	Sep 21, 2026	BUY	Strong Buy +1250.4% avg upside 12 analysts	$5.00 1008.00% Upside	-36.4%	·
VYGR Voyager Therapeutics	Sep 21, 2026	BUY	Strong Buy +569.7% avg upside 23 analysts	$25.00 1090.47% Upside	-26.3%	·
MRKR Marker Therapeutics	Sep 21, 2026	BUY	Strong Buy +1421.5% avg upside 9 analysts	$10.00 981.17% Upside	-13.3%	·
GB:FARN Faron Pharmaceuticals Oy	Sep 21, 2026	BUY	Strong Buy +2751.4% avg upside 1 analyst	$1000.00 2751.36% Upside	+4.3%	·
NRXP NRX Pharmaceuticals	Sep 21, 2026	BUY	Strong Buy +1314.4% avg upside 5 analysts	$45.00 1604.46% Upside	-13.4%	·
GOSS Gossamer Bio	Sep 21, 2026	BUY	Buy +1485.2% avg upside 17 analysts	$90.00 869.91% Upside	-18.7%	·
DTIL Precision BioSciences	Sep 21, 2026	BUY	Strong Buy +285.1% avg upside 12 analysts	$60.00 900.09% Upside	+3.4%	·
SLN Silence Therapeutics	Sep 21, 2026	BUY	Strong Buy +286.9% avg upside 10 analysts	$75.00 747.44% Upside	-27.6%	·
FTH Faeth Therapeutics	Sep 21, 2026	BUY	Strong Buy +126.3% avg upside 20 analysts	$60.00 196.64% Upside	-21.8%	·
IMCR Immunocore Holdings	Sep 21, 2026	BUY	Strong Buy +127.6% avg upside 22 analysts	$100.00 261.19% Upside	-9.8%	·
DRUG Bright Minds Biosciences	Sep 21, 2026	BUY	Strong Buy +166.5% avg upside 11 analysts	$145.00 195.01% Upside	-14.7%	·
ANRO Alto Neuroscience, Inc.	Sep 21, 2026	BUY	Strong Buy +44.4% avg upside 13 analysts	$55.00 148.99% Upside	-29.1%	·
DFTX Definium Therapeutics	Sep 15, 2026	BUY	Strong Buy +57.2% avg upside 24 analysts	$70.00 107.49% Upside	-6.6%	·
BEAM Beam Therapeutics	Sep 09, 2026	BUY	Strong Buy +115.0% avg upside 25 analysts	$80.00 236.41% Upside	-4.2%	·
GHRS GH Research	Aug 10, 2026	BUY	Strong Buy +110.3% avg upside 12 analysts	$65.00 244.91% Upside	-32.2%	·
SGMOQ Sangamo Therapeutics	Jun 09, 2026	HOLD	Buy +7827.3% avg upside 16 analysts	—	+0.0%	·
MIST Milestone Pharmaceuticals	Apr 02, 2025	BUY	Strong Buy +872.7% avg upside 8 analysts	$10.00 1228.74% Upside	+71.9%	·
QTTB Q32 Bio	May 15, 2023	BUY	Strong Buy +594.5% avg upside 28 analysts	$360.00 4557.16% Upside	+60.1%	·
BNTC Benitec Biopharma	Feb 10, 2023	HOLD	Strong Buy +197.3% avg upside 14 analysts	—	-37.9%	·
TSE:PHRM PharmaTher Holdings Ltd	Feb 10, 2023	HOLD	Hold 1 analyst	—	+19.5%	·
GB:AGY Allergy Therapeutics	Nov 02, 2022	BUY	Strong Buy +44088.6% avg upside 2 analysts	$46.03 885.73% Upside	-90.6%	·
DE:EVT Evotec	Mar 27, 2020	BUY	Buy +553.1% avg upside 8 analysts	$33.00 1144.30% Upside	+46.1%	·
SUPN Supernus Pharmaceuticals	Nov 08, 2019	HOLD	Strong Buy +32.3% avg upside 9 analysts	$24.00 42.93% Downside	+8.6%	·
ENTA Enanta Pharmaceuticals	Sep 18, 2019	BUY	Buy +188.1% avg upside 17 analysts	$130.00 1042.27% Upside	-34.7%	·
PRGO Perrigo Company	Nov 13, 2018	HOLD	Buy +337.8% avg upside 20 analysts	$72.00 366.95% Upside	-24.8%	·
IRWD Ironwood Pharma	Apr 19, 2018	BUY	Buy +229.8% avg upside 23 analysts	$25.00 603.22% Upside	-23.6%	·
INVA Innoviva	Apr 19, 2018	BUY	Buy +40.3% avg upside 13 analysts	$22.00 5.59% Upside	-19.3%	·
KMB Kimberly Clark	Dec 23, 2014	BUY	Buy +27.3% avg upside 30 analysts	$125.00 25.58% Upside	+11.2%	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Patrick Trucchio — Frequently Asked Questions

How accurate are Patrick Trucchio's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Patrick's ratings were profitable over a one-year hold, with an average return of +0.5% per rating, or -1.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Patrick ranked on 13Foresight?

Patrick Trucchio is currently ranked #1581 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Patrick cover?

Patrick most recently has ratings on HRMY, ALGS, HELP, ASMB, ALT, VIR, PHVS, AGMB, IVVD, QURE, CMPS, ALNY and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Patrick Trucchio

Rating Distribution

Welcome to 13Foresight!